Skip to main content

Table 2 pCR Rates by clinical characteristics

From: Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Characteristic N non-pCR, n (%) pCR, n (%) P-value
Total 2334 1874 (80.3) 460 (19.7)  
Age     0.49
  ≤50y 1415 1129 (79.8) 286 (20.2)  
  >50y 919 745 (81.1) 174 (18.9)  
ER     <0.001
  Positive 1365 1202 (88.1) 163 (11.9)  
  Negative 969 672 (69.3) 297 (30.7)  
PgR     <0.001
  Positive 1108 984 (88.8) 124 (11.2)  
  Negative 1226 890 (72.6) 336 (27.4)  
HER2     <0.001
  Positive 714 521 (73.0) 193 (27.0)  
  Negative 1620 1353 (83.5) 267 (16.5)  
TNBC     <0.001
Non-TNBC 1837 1517 (82.6) 320 (17.4)  
TNBC 497 357 (71.8) 140 (28.2)  
Tumor size     
  <2 cm 786 596 (75.8) 190 (24.2) <0.001
  ≥2 cm 1548 1278 (82.6) 270 (17.4)  
Lymph node     
  Positive 1014 892(88.0) 122 (12.0) <0.001
  Negative 1314 978(74.4) 336 (25.6)  
Nuclear grade     
  1 199 174 (87.4) 25 (12.6) <0.001
  2 1518 1252 (82.5) 266 (17.5)  
  3 302 184 (60.9) 118 (39.1)  
Histology     0.60
  Ductal 2064 1654 (80.1) 410 (19.9)  
  Others 270 220 (81.5) 50 (18.5)  
CHEK2 H371Y     0.031
  Non-carriers 2295 1848 (80.5) 447 (19.5)  
  Carriers 39 26(66.7) 13 (33.3)  
Chemotherapy type     0.50
  A-based,without a T 859 700 (81.5) 159 (18.5)  
  A-T containing 882 705 (79.9) 177 (20.1)  
  T-based,without a A 593 469 (79.1) 124 (20.9)  
Trastuzumab use     <0.001
  Yes 108 61 (57.1) 47 (43.5)  
  No 2225 1812 (81.4) 413 (18.6)  
Surgery type     <0.001
  BCS 983 756 (76.9) 227 (23.1)  
  Mastectomy 1351 1118 (82.8) 233 (17.2)  
  1. pCR, pathologic complete response; ER, Estrogen receptor; PgR, Progesterone receptor; HER2, Human epidermal growth factor receptor-2; A, Anthracycline; T, Taxane; BCS, Breast-conserving surgery.